NDAOPHTHALMICSOLUTION/DROPS
Approved
Nov 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
5/8 — Partial
MOXEZA (moxifloxacin hydrochloride) by Teva is 12. Approved for bacterial conjunctivitis, community-acquired pneumonia, copd exacerbation. First approved in 2010.
Drug data last refreshed 20h ago
Mechanism of Action
12.1 Mechanism of Action Moxifloxacin hydrochloride is a member of the fluoroquinolone class of antibacterial agents [see ] . 12.2 Pharmacodynamics Photosensitivity Potential A study of the skin response to ultraviolet (UVA and UVB) and visible radiation conducted in 32 healthy volunteers (8 per…
Worked on MOXEZA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.